Open
biosensors.
Your data
pays you.
Open hardware · user-owned biometric data · onchain payouts.
A $90B sensor market runs on hardware you can’t open and data you don’t own. Both just became fixable.
$450/yr
what a user spends on wearables
closed firmware, vendor app only — Apple, Oura, Whoop, Abbott, Dexcom
0¢
what they pay you for your data
biometric data is aggregated, siloed, and sold — the wearer captures none of it
−90%
optical sensor cost since 2020
research-grade optics now fit a <$500 consumer device — and onchain rails can pay contributors
Cheap optics + 500M wearable users + zero open alternatives. The unlock isn’t a new sensor — it’s who owns the data it produces.
The only open biosensor that pays its wearer. Shipped.
Hardware — v2 in production
Light-based headband & armband. 4 circuit boards manufactured and tested. Built with Vanderbilt’s Bowden Lab.
Software — upload, train, get paid
Web app for raw sensor ingestion, model training, and onchain reward claims.
Dataset — first of its kind
Open paired light–glucose data with reproducible ML pipelines. First beachhead: glucose-trend prediction.
Auth, payments & agent rails run in production at chat.think2earn.com — the data marketplace reuses them at zero marginal build cost.
v2 device — controller, enclosure, sensor array
Data flows to researchers. Money flows back to wearers.
TODAY: your data → their cloud → their revenue. You get $0.
Wears the device, runs local health models
LOCAL · SOVEREIGN
Auditable protocol meters access & routes payment
OPEN-SOURCE · VERIFIABLE
Labs & AI teams pay for verified, anonymized insight
NEVER RAW DATA
Open
Schematics & firmware on GitHub. Anyone can build, improve, audit. <$500/unit.
Yours
Data stays on-device unless shared. When you share, you earn — paid onchain.
Proven
Every payout cryptographically verifiable — zero-knowledge ML, onchain receipts.
Four buyer groups, one device. Glucose is the wedge — the rest is a firmware update.
REACHABLE REVENUE — YEAR 5, FOUR SCENARIOS
CONSERVATIVE
$10M
biohackers only
EXPECTED
$45M
wellness wins
BULL
$120M
non-invasive flip
MEGA BULL
$300M
biometric OS
SAM PER USE CASE — SAME HARDWARE, DIFFERENT CUSTOMER
Hardware at 63% margin funds the dataset. The dataset compounds into licensing revenue.
$150
COST AT 200 UNITS
$400
RETAIL PRICE
63%
GROSS MARGIN
0
SUBSCRIPTION DRAG
THE MOAT
Open hardware, private dataset. Incumbents can’t copy without killing sensor revenue. Forks start at zero. We compound per unit shipped.
REVENUE 01
Device sales
D2C at $400–600. One-time purchase, no subscription.
REVENUE 02
Dataset licensing
Universities & labs pay USDC for verified, paired biometric data.
REVENUE 03
Marketplace fees
Take rate on researcher ↔ contributor exchanges as the network opens.
Device + data revenue → 30% of gross profit to onchain buyback → stronger token → bigger contributor rewards → more devices, more data.
Everyone else is closed, invasive, or doesn’t pay the user.
SOURCES: DEXCOM G7 & ABBOTT LIBRE 3 PLUS SPECS (MARD 8.2%) · KNOW LABS NYSE DELISTING JAN 2025 · OPENBCI SHOP PRICING · CUDIS RING + $CUDIS LAUNCH, JUN 2025
Closed CGMs cost $2,400+/yr. Open EEG kits don’t earn. We sit in the overlap nobody ships.
≈$71k of non-dilutive validation before raising a cent.
$17.5k
NEAR Protocol Rewards
Diamond tier · staking that pays when data provably improves models
$8k
Ocean Protocol Foundation
Research grant · NIRDuino build + paired light–glucose dataset
$3k
EigenLayer AI Competition
Vibescore Top 5 — won with think2earn
Finalist
ETHGlobal Cannes 2025
ENS Most Creative 2nd · $10k AWS credits
+ ZuVillage Georgia $3k (Best Startup · Best Project) · Deep Funding $2k (3rd of 12,125, Vitalik-sponsored) · Linea 2nd $1k · ETHDam Waku ~$1k · ZuThailand EZKL $500
BUILD CREDITS — $35K, FUNDING APP DEVELOPMENT
$20k Hyperagent Founding 500 · $10k AWS via ETHGlobal Cannes finalist · $5k Thinking Machines (Tinker)
RESIDENCIES & STAGE
MegaZU (panel judged alongside Vitalik) · The Vault Berlin (EigenLayer AVS) · Zuitzerland ×2 (Logos + track) · ETHGlobal Buenos Aires (Curvegrid) · ZuThailand fellow
NIRDuino open fNIRS hardware with Vanderbilt’s Bowden Lab · first public paired light–glucose dataset · chat.think2earn.com live — the agent & payment rails the marketplace runs on.
Built by the person wearing the device.
Tudor ADVISOR
OpenAI Member of Technical Staff · on leave from Stanford postdoc · ex-CTRL-Labs (Meta).
COLLABORATOR
Bowden Lab at Vanderbilt University
USDC pays the bills. Profit buys the token. Emissions can never outrun the buyback.
Hardware + data licensing, paid in USDC by default — or stake $T2E instead (dual rails).
30% of gross profit → public onchain contract, TWAP buys — no discretion, no front-running. Bought $T2E → protocol-owned liquidity until a depth target, then 100% burn.
Pegged to the buyback: at most $0.75 minted per $1.00 repurchased — supply contracts by construction, no assumptions required.
Staked $T2E = a fixed daily API allowance — dataset queries, model access, agent tools. Using the product means buying and holding it.
Pay in $T2E → 15% discount, tokens burned · quality bonds on data uploads — junk gets slashed.
Payment & agent rails
chat.think2earn.com
Encrypted data sharing
same rails, private datasets
Fair payouts
contributors paid onchain
SUPPLY — 100M FIXED
Contributor tokens unemitted at year 8 are burned — the pool is a ceiling, not a schedule. No hidden overhang.
Investors & team: 2-yr cliff, 4-yr vest. Insiders 30% total. Staked $T2E governs emission splits, bounties, treasury.
$150K turns a shipped device into a validated dataset company.
$3M SAFE · 5 MONTHS · 2 MILESTONES · UNLOCKS SEED
$50K
PHASE 1 — M 1–2
Ship the platform
- — 50 open-hardware units manufactured
- — Data ingestion + ML training pipeline
- — Payout rails: Base L2, x402, EIP-3009
$100K
PHASE 2 — M 3–5
Validate first vertical
- — 100-person glucose-trend trial (CGM + finger-prick ground truth)
- — Leave-one-subject-out cross-validation
- — Lock the model. Prove the loop.
Seed
OUTCOME — M 6+
Open dataset + working loop
- — First-of-kind paired biometric dataset
- — Validated glucose-trend model in production
- — Clinical evidence pipeline for EU MDR
DE-RISKED
Kill criterion pre-named: if glucose-trend accuracy misses the bar, the same hardware pivots to cognitive load — the dataset and platform survive the pivot. Launches as wellness & research device (no FDA/MDR gate). $35k in build credits already offsets infra.
WHAT YOU FUND
An open biosensor platform, a first-of-kind paired dataset, and the loop proof that unlocks every adjacent vertical. Swiss association (Zug) = clean token pathway.